GlassScriptPhysician profile
Kevin Brigle
NPI 1912081571
$165,987.75
in general payments reported to CMS, 2019-2025
22 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28K · 2022: $34K · 2023: $42K · 2024: $36K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53K · Consulting Fee: $20K · Travel and Lodging: $11K · Honoraria: $8,250 · Food and Beverage: $5,668 · Grant: $5,282 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $250 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,009.00 |
| Consulting Fee | $20,238.75 |
| Travel and Lodging | $11,361.76 |
| Honoraria | $8,250.00 |
| Food and Beverage | $5,668.19 |
| Grant | $5,282.22 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $250.00 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $37,748.15 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $25,572.68 | 2021-2025 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $20,278.97 | 2021-2025 | Calquence, Enhertu |
| Pfizer INC. | $16,240.69 | 2023-2025 | |
| Janssen Biotech, INC. | $15,488.09 | 2023-2025 | Carvykti, Tecvayli, Darzalex |
| Karyopharm Therapeutics INC. | $13,893.10 | 2021-2025 | Xpovio |
| Celgene Corporation | $9,065.36 | 2021-2024 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $8,894.33 | 2022-2024 | Ninlaro, Iclusig |
| Abbvie INC. | $6,110.20 | 2021-2023 | |
| Legend Biotech USA INC. | $2,559.35 | 2025 | |
| Amgen INC. | $1,945.12 | 2021 | |
| Seagen INC. | $1,712.33 | 2021 | |
| Incyte Corporation | $1,710.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $1,121.81 | 2024-2025 | Talvey, Carvykti, Tecvayli |
| Beigene, LTD. | $1,040.00 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $900.00 | 2022 | |
| Genmab U.S., INC. | $839.27 | 2024 | Epkinly |
| Glaxosmithkline, LLC. | $542.50 | 2021 | |
| Blueprint Medicines Corporation | $116.99 | 2024 | Ayvakit |
| Gilead Sciences, INC. | $88.25 | 2021 | |
| Sobi, INC | $80.70 | 2022 | |
| Johnson & Johnson Health Care Systems INC. | $39.86 | 2024 | Tecvayli, Talvey, Darzalex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Brigle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.